Answers are grounded in this paper and cite their sources.
A Physical Sciences Perspective of the Evolution of Drug Resistance in CancerI n this day and age with advanced technologies for the detection and diagnosis of cancer, the treatment to cure or even to control cancer remains a challenge greatly due to the evolution of resistance to available treatments.It is estimated that in the United States 1,530,000 people were diagnosed with and 570,000 people died of cancer of all sites in 2010 [http://seer.cancer.gov/csr/ 1975_2007/results_single/sect_01_table.01.pdf].Most cancer-related deaths are not due to cancer in the primary site; rather, the deaths are due to disseminated disease when metastasis occurs in vital organs such as the liver, lungs, or pancreas.Relapse in cancer patients undergoing therapy is by and large due to the evolution of drug resistance in the cancer cell population.Evolutionary theory predicts that, given time, heredity, and variation, any living organisms will evolve when a selective pressure is introduced.Albeit much more complex, the evolution of drug resistance in cancer is akin to the evolution of antibiotic drug resistance in bacteria, where evolutionary theory has been applied to suggest specific strategies to delay the onset of drug resistance.In October 2009 the Physical SciencesOncology Centers (PS-OCs) Program was launched by the Office of Physical SciencesOncology (OPSO) of the National Cancer Institute (NCI) to tackle longstanding problems in cancer biology and oncology with a physical sciences perspective.Across the country, twelve PS-OCs were established to form a PS-OC Network bringing together for the first time teams of experts from the physical and biological sciences to study cancer at a fundamental level.Thematic areas around which the PS-OCs formed are (1) the physical laws and principals of cancer; (2) information coding, decoding, transfer and translation in cancer;(3) deconvoluting cancer's complexity; and (4) evolution and evolutionary theory in cancer.A subtheme of the lattermost is the topic for this special issue of Molecular Pharmaceutics: Evolution of Drug Resistance in Cancer.To cover the breadth of the topic for this special issue, contributions were solicited from scientific investigators both within and beyond the PS-OC Evolution of Drug Resistance Working Group to illustrate the problem of drug resistance in cancer and describe potential solutions from multiple vantage points.Investigators from the PS-OC Program who contributed to this special issue are conducting exciting work in the thematic area of evolution and evolutionary theory in cancer.Franziska Michor and colleagues at the Dana-Farber Cancer Institute PS-OC are using evolutionary biology in combination with theoretical mathematical modeling to shed light on the optimization of dosing schedules for cancer chemotherapy. 1,2olleagues at the University of Southern California PS-OC including David Agus and Parag Mallick provide experimental results for input of parameters into the evolutionary mathematical models developed by Michor that predict the penetrance of drug resistance. 9Robert Austin at the Princeton University PS-OC is using microfabricated habitats to examine evolution of drug resistance in bacteria in response to selective pressure, and has shown that within hours bacteria can develop resistance to antibiotics which is attributed to four single
No takes yet. Share an insight, caveat, or question.
Kuhn et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: